|
 |
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
|
Mutations associated with resistance |
Mutations associated with « possible resistance » |
ZDV
|
T215A/C/D/E/G/H/I/L/N/S/V/Y/F [1, 2, 3, 4]
 |
At least 3 mutations among: M41L, D67N, K70R, L210W, K219Q/E [1, 2, 3, 4] |
Q151M
Insertion at codon 69
|
|
3TC/FTC
|
K65R [8, 9, 11]
M184V/I
Insertion at codon 69
|
Q151M
|
ABC
|
 |
At least 3 mutations among: M41L, D67N, M184V/I, L210W, T215A/C/D/E/G/H/I/L/N/S/V/Y/F [5, 20] |
K65R [6, 8, 9, 24]
L74V/I [16, 17, 18, 19, 20, 24]
Y115F [24]
Q151M
Insertion at codon 69
|
 |
2 mutations among: M41L, D67N, L210W, T215A/C/D/E/G/H/I/L/N/S/V/Y/F [5, 20] |
M184V/I [24] |
TDF/TAF
|
 |
At least 4 mutations among: M41L, E44D, D67N, T69D/N/S, L74V/I, L210W, T215A/C/D/E/G/H/I/L/N/S/V/Y/F [10, 12, 21, 25, 26] |
K65R/E/N [6, 7, 8, 9, 22, 23, 25, 26]
Insertion at codon 69
K70E [13, 14, 15] |
 |
3 mutations among: M41L, E44D, D67N, T69D/N/S, L74V/I, L210W, T215A/C/D/E/G/H/I/L/N/S/V/Y/F [10, 12, 21, 25, 26] |
|
ISL
|
M184V/I [27,28,29]
|
A114S [29] |
ZDV: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ddI: didanosine, d4T: stavudine, ABC: abacavir, TDF: tenofovir, TAF : tenofovir alafenamide, ISL: islatravir.
For didanosine and stavudine refer to previous rules (See Archives, September 2017, version 27)
For DNA provirus, impact of stop codons and G->A mutations on ARV resistance is unknown.
References |
 |
|
|